Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Yea... (net sales decreased $13.7 million or 76....)

Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance

Date:11/10/2008

net sales decreased $13.7 million, or 76.6%, in the quarter ended September 30, 2008, compared to the same quarter last year. The decrease in ESTROSTEP FE net sales was primarily due to an 83.2% decline in filled prescriptions versus the prior year quarter as a result of the introduction of generic versions of ESTROSTEP FE in the fourth quarter of 2007, including our authorized generic Tilia(TM) FE. Our revenue from net sales of Tilia(TM) FE partially offset the decline in ESTROSTEP FE net sales.

Net sales of our dermatology products increased $15.1 million, or 15.9%, in the quarter ended September 30, 2008, compared to the prior year quarter. Sales of DORYX increased $15.6 million, or 53.3%, in the quarter ended September 30, 2008, primarily due to an expansion of pipeline inventories primarily resulting from the launch of DORYX 150 mg in the quarter ended September 30, 2008. Also contributing to the increase, to a lesser extent, were higher average selling prices and a 12.9% increase in filled prescriptions compared to the prior year quarter. Net sales of TACLONEX increased $5.1 million, or 15.3%, to $38.2 million in the quarter ended September 30, 2008, compared to $33.1 million in the prior year quarter. The increase was primarily due to the introduction of TACLONEX scalp in June 2008, higher average selling prices and an increase in the average grams per filled prescription in the quarter ended September 30, 2008 compared to the prior year quarter. Sales of DOVONEX decreased $5.6 million, or 17.6%, in the quarter ended September 30, 2008, compared to the prior year quarter. The decline in DOVONEX net sales was due primarily to a 25.4% decrease in filled prescriptions and increases in sales-related deductions in the third quarter of 2008, which was partially offset by higher average selling prices. The decline in filled prescriptions of DOVONEX was due primarily to the introduction of generic versions of DOVONEX solution into the market in the second quar
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine news :

1. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2008 Financial Results
2. House Passes Historic Bill to Protect Kids From Tobacco; Senators Webb & Warner Should Cosponsor Legislation
3. Fitness and Figure Professionals Kirsten Nicewarner and Michelle Adams to Represent GNC at Vails Teva Mountain Games
4. The Oregon Clinic Extends Patient Care Services Across Metro Portland with Time Warner Telecoms Metro Ethernet Service
5. Warner Chilcott Announces Settlement of Securities Litigation
6. LodgeNet Appoints John E. Haire, Former Time Warner Executive, to Board of Directors
7. CooperVision Increases Network Performance While Reducing Costs With Time Warner Telecoms IP VPN
8. Sharing Miracles Television Program to Feature Mountain Climber and Cancer Survivor Sean Swarner
9. Pinstripe Healthcare Group Adds Veteran HR Executive Warner as Client Services Director
10. Warner Chilcott Announces 2008 Financial Guidance
11. Warner Chilcott to Present at the 2008 Wachovia Healthcare Conference

Post Your Comments:

Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Yea...(net sales decreased $13.7 million or 76....),Health